Cargando…
The added value of PSMA PET/MR radiomics for prostate cancer staging
PURPOSE: To evaluate the performance of combined PET and multiparametric MRI (mpMRI) radiomics for the group-wise prediction of postsurgical Gleason scores (psGSs) in primary prostate cancer (PCa) patients. METHODS: Patients with PCa, who underwent [(68) Ga]Ga-PSMA-11 PET/MRI followed by radical pro...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8803696/ https://www.ncbi.nlm.nih.gov/pubmed/34255130 http://dx.doi.org/10.1007/s00259-021-05430-z |
_version_ | 1784642924059820032 |
---|---|
author | Solari, Esteban Lucas Gafita, Andrei Schachoff, Sylvia Bogdanović, Borjana Villagrán Asiares, Alberto Amiel, Thomas Hui, Wang Rauscher, Isabel Visvikis, Dimitris Maurer, Tobias Schwamborn, Kristina Mustafa, Mona Weber, Wolfgang Navab, Nassir Eiber, Matthias Hatt, Mathieu Nekolla, Stephan G. |
author_facet | Solari, Esteban Lucas Gafita, Andrei Schachoff, Sylvia Bogdanović, Borjana Villagrán Asiares, Alberto Amiel, Thomas Hui, Wang Rauscher, Isabel Visvikis, Dimitris Maurer, Tobias Schwamborn, Kristina Mustafa, Mona Weber, Wolfgang Navab, Nassir Eiber, Matthias Hatt, Mathieu Nekolla, Stephan G. |
author_sort | Solari, Esteban Lucas |
collection | PubMed |
description | PURPOSE: To evaluate the performance of combined PET and multiparametric MRI (mpMRI) radiomics for the group-wise prediction of postsurgical Gleason scores (psGSs) in primary prostate cancer (PCa) patients. METHODS: Patients with PCa, who underwent [(68) Ga]Ga-PSMA-11 PET/MRI followed by radical prostatectomy, were included in this retrospective analysis (n = 101). Patients were grouped by psGS in three categories: ISUP grades 1–3, ISUP grade 4, and ISUP grade 5. mpMRI images included T1-weighted, T2-weighted, and apparent diffusion coefficient (ADC) map. Whole-prostate segmentations were performed on each modality, and image biomarker standardization initiative (IBSI)-compliant radiomic features were extracted. Nine support vector machine (SVM) models were trained: four single-modality radiomic models (PET, T1w, T2w, ADC); three PET + MRI double-modality models (PET + T1w, PET + T2w, PET + ADC), and two baseline models (one with patient data, one image-based) for comparison. A sixfold stratified cross-validation was performed, and balanced accuracies (bAcc) of the predictions of the best-performing models were reported and compared through Student’s t-tests. The predictions of the best-performing model were compared against biopsy GS (bGS). RESULTS: All radiomic models outperformed the baseline models. The best-performing (mean ± stdv [%]) single-modality model was the ADC model (76 ± 6%), although not significantly better (p > 0.05) than other single-modality models (T1w: 72 ± 3%, T2w: 73 ± 2%; PET: 75 ± 5%). The overall best-performing model combined PET + ADC radiomics (82 ± 5%). It significantly outperformed most other double-modality (PET + T1w: 74 ± 5%, p = 0.026; PET + T2w: 71 ± 4%, p = 0.003) and single-modality models (PET: p = 0.042; T1w: p = 0.002; T2w: p = 0.003), except the ADC-only model (p = 0.138). In this initial cohort, the PET + ADC model outperformed bGS overall (82.5% vs 72.4%) in the prediction of psGS. CONCLUSION: All single- and double-modality models outperformed the baseline models, showing their potential in the prediction of GS, even with an unbalanced cohort. The best-performing model included PET + ADC radiomics, suggesting a complementary value of PSMA-PET and ADC radiomics. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00259-021-05430-z. |
format | Online Article Text |
id | pubmed-8803696 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-88036962022-02-02 The added value of PSMA PET/MR radiomics for prostate cancer staging Solari, Esteban Lucas Gafita, Andrei Schachoff, Sylvia Bogdanović, Borjana Villagrán Asiares, Alberto Amiel, Thomas Hui, Wang Rauscher, Isabel Visvikis, Dimitris Maurer, Tobias Schwamborn, Kristina Mustafa, Mona Weber, Wolfgang Navab, Nassir Eiber, Matthias Hatt, Mathieu Nekolla, Stephan G. Eur J Nucl Med Mol Imaging Original Article PURPOSE: To evaluate the performance of combined PET and multiparametric MRI (mpMRI) radiomics for the group-wise prediction of postsurgical Gleason scores (psGSs) in primary prostate cancer (PCa) patients. METHODS: Patients with PCa, who underwent [(68) Ga]Ga-PSMA-11 PET/MRI followed by radical prostatectomy, were included in this retrospective analysis (n = 101). Patients were grouped by psGS in three categories: ISUP grades 1–3, ISUP grade 4, and ISUP grade 5. mpMRI images included T1-weighted, T2-weighted, and apparent diffusion coefficient (ADC) map. Whole-prostate segmentations were performed on each modality, and image biomarker standardization initiative (IBSI)-compliant radiomic features were extracted. Nine support vector machine (SVM) models were trained: four single-modality radiomic models (PET, T1w, T2w, ADC); three PET + MRI double-modality models (PET + T1w, PET + T2w, PET + ADC), and two baseline models (one with patient data, one image-based) for comparison. A sixfold stratified cross-validation was performed, and balanced accuracies (bAcc) of the predictions of the best-performing models were reported and compared through Student’s t-tests. The predictions of the best-performing model were compared against biopsy GS (bGS). RESULTS: All radiomic models outperformed the baseline models. The best-performing (mean ± stdv [%]) single-modality model was the ADC model (76 ± 6%), although not significantly better (p > 0.05) than other single-modality models (T1w: 72 ± 3%, T2w: 73 ± 2%; PET: 75 ± 5%). The overall best-performing model combined PET + ADC radiomics (82 ± 5%). It significantly outperformed most other double-modality (PET + T1w: 74 ± 5%, p = 0.026; PET + T2w: 71 ± 4%, p = 0.003) and single-modality models (PET: p = 0.042; T1w: p = 0.002; T2w: p = 0.003), except the ADC-only model (p = 0.138). In this initial cohort, the PET + ADC model outperformed bGS overall (82.5% vs 72.4%) in the prediction of psGS. CONCLUSION: All single- and double-modality models outperformed the baseline models, showing their potential in the prediction of GS, even with an unbalanced cohort. The best-performing model included PET + ADC radiomics, suggesting a complementary value of PSMA-PET and ADC radiomics. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00259-021-05430-z. Springer Berlin Heidelberg 2021-07-13 2022 /pmc/articles/PMC8803696/ /pubmed/34255130 http://dx.doi.org/10.1007/s00259-021-05430-z Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Solari, Esteban Lucas Gafita, Andrei Schachoff, Sylvia Bogdanović, Borjana Villagrán Asiares, Alberto Amiel, Thomas Hui, Wang Rauscher, Isabel Visvikis, Dimitris Maurer, Tobias Schwamborn, Kristina Mustafa, Mona Weber, Wolfgang Navab, Nassir Eiber, Matthias Hatt, Mathieu Nekolla, Stephan G. The added value of PSMA PET/MR radiomics for prostate cancer staging |
title | The added value of PSMA PET/MR radiomics for prostate cancer staging |
title_full | The added value of PSMA PET/MR radiomics for prostate cancer staging |
title_fullStr | The added value of PSMA PET/MR radiomics for prostate cancer staging |
title_full_unstemmed | The added value of PSMA PET/MR radiomics for prostate cancer staging |
title_short | The added value of PSMA PET/MR radiomics for prostate cancer staging |
title_sort | added value of psma pet/mr radiomics for prostate cancer staging |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8803696/ https://www.ncbi.nlm.nih.gov/pubmed/34255130 http://dx.doi.org/10.1007/s00259-021-05430-z |
work_keys_str_mv | AT solariestebanlucas theaddedvalueofpsmapetmrradiomicsforprostatecancerstaging AT gafitaandrei theaddedvalueofpsmapetmrradiomicsforprostatecancerstaging AT schachoffsylvia theaddedvalueofpsmapetmrradiomicsforprostatecancerstaging AT bogdanovicborjana theaddedvalueofpsmapetmrradiomicsforprostatecancerstaging AT villagranasiaresalberto theaddedvalueofpsmapetmrradiomicsforprostatecancerstaging AT amielthomas theaddedvalueofpsmapetmrradiomicsforprostatecancerstaging AT huiwang theaddedvalueofpsmapetmrradiomicsforprostatecancerstaging AT rauscherisabel theaddedvalueofpsmapetmrradiomicsforprostatecancerstaging AT visvikisdimitris theaddedvalueofpsmapetmrradiomicsforprostatecancerstaging AT maurertobias theaddedvalueofpsmapetmrradiomicsforprostatecancerstaging AT schwambornkristina theaddedvalueofpsmapetmrradiomicsforprostatecancerstaging AT mustafamona theaddedvalueofpsmapetmrradiomicsforprostatecancerstaging AT weberwolfgang theaddedvalueofpsmapetmrradiomicsforprostatecancerstaging AT navabnassir theaddedvalueofpsmapetmrradiomicsforprostatecancerstaging AT eibermatthias theaddedvalueofpsmapetmrradiomicsforprostatecancerstaging AT hattmathieu theaddedvalueofpsmapetmrradiomicsforprostatecancerstaging AT nekollastephang theaddedvalueofpsmapetmrradiomicsforprostatecancerstaging AT solariestebanlucas addedvalueofpsmapetmrradiomicsforprostatecancerstaging AT gafitaandrei addedvalueofpsmapetmrradiomicsforprostatecancerstaging AT schachoffsylvia addedvalueofpsmapetmrradiomicsforprostatecancerstaging AT bogdanovicborjana addedvalueofpsmapetmrradiomicsforprostatecancerstaging AT villagranasiaresalberto addedvalueofpsmapetmrradiomicsforprostatecancerstaging AT amielthomas addedvalueofpsmapetmrradiomicsforprostatecancerstaging AT huiwang addedvalueofpsmapetmrradiomicsforprostatecancerstaging AT rauscherisabel addedvalueofpsmapetmrradiomicsforprostatecancerstaging AT visvikisdimitris addedvalueofpsmapetmrradiomicsforprostatecancerstaging AT maurertobias addedvalueofpsmapetmrradiomicsforprostatecancerstaging AT schwambornkristina addedvalueofpsmapetmrradiomicsforprostatecancerstaging AT mustafamona addedvalueofpsmapetmrradiomicsforprostatecancerstaging AT weberwolfgang addedvalueofpsmapetmrradiomicsforprostatecancerstaging AT navabnassir addedvalueofpsmapetmrradiomicsforprostatecancerstaging AT eibermatthias addedvalueofpsmapetmrradiomicsforprostatecancerstaging AT hattmathieu addedvalueofpsmapetmrradiomicsforprostatecancerstaging AT nekollastephang addedvalueofpsmapetmrradiomicsforprostatecancerstaging |